



(12) **CORRECTED EUROPEAN PATENT APPLICATION**
published in accordance with Art. 153(4) EPC

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Abstract

(51) Int Cl.:
C07C 233/47 ^(2006.01) **C07C 231/24** ^(2006.01)
C07D 257/04 ^(2006.01) **A61P 9/04** ^(2006.01)

(48) Corrigendum issued on:
11.04.2018 Bulletin 2018/15

(86) International application number:
PCT/CN2016/076660

(43) Date of publication:
24.01.2018 Bulletin 2018/04

(87) International publication number:
WO 2016/150337 (29.09.2016 Gazette 2016/39)

(21) Application number: **16767714.5**

(22) Date of filing: **18.03.2016**

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
MA MD

- **ZHANG, Yanfeng**
Suzhou
Jiangsu 215123 (CN)
- **YANG, Chaohui**
Suzhou
Jiangsu 215123 (CN)
- **YU, Shu**
Suzhou
Jiangsu 215123 (CN)
- **ZHANG, Xiaoyu**
Suzhou
Jiangsu 215123 (CN)
- **ZHANG, Liang**
Shanghai 200136 (CN)

(30) Priority: **20.03.2015 CN 201510124555**


(71) Applicant: **Crystal Pharmatech Co., Ltd.**
Suzhou, Jiangsu 215123 (CN)

(72) Inventors:
• **CHEN, Minhua**
Suzhou
Jiangsu 215123 (CN)

(74) Representative: **Grünecker Patent- und**
Rechtsanwälte
PartG mbB
Leopoldstraße 4
80802 München (DE)

(54) **AHU377 CRYSTAL FORM, PREPARATION METHOD AND USE THEREOF**

(57) The present disclosure relates to a novel crystalline form of a compound of formula (I), preparation method and use thereof. The novel crystalline form in the present disclosure has good stability, low hygroscopicity, and remarkable purification effect in process. The novel crystalline form of the compound of formula (I) provided by the present disclosure can be used for the preparation of the drug for treating heart failure.






Fig. 1